Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Mineralys Therapeutics Inc - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH
Ticker
Exchange
SIC #
Website
Latest Ticker
MLYS
Nasdaq
8731
https://mineralystx.com/
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Mineralys Therapeutics Inc
Goldman Sachs Predicts Over 120% Rally for These 2 ‘Strong Buy’ Stocks
- Apr 5th, 2024 4:16 am
Mineralys Therapeutics, Inc. (NASDAQ:MLYS) Q4 2023 Earnings Call Transcript
- Mar 22nd, 2024 2:51 pm
Mineralys Therapeutics Inc (MLYS) Reports Increased R&D Expenses Amid Progress in ...
- Mar 21st, 2024 1:11 pm
Mineralys Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
- Mar 21st, 2024 11:00 am
Mineralys Therapeutics to Announce Fourth Quarter and Full Year 2023 Financial Results and Host Conference Call on Thursday, March 21, 2024
- Mar 13th, 2024 8:05 pm
Mineralys Therapeutics Announces $120 Million Private Placement Financing
- Feb 8th, 2024 1:00 pm
Mineralys Therapeutics to Participate in the Guggenheim Securities 6th Annual Biotechnology Conference
- Jan 29th, 2024 9:05 pm
Mineralys Therapeutics, Inc. (MLYS) Upgraded to Strong Buy: Here's What You Should Know
- Jan 17th, 2024 5:00 pm
Mineralys Therapeutics Appoints Minji Kim, Ph.D. as Chief Business Officer
- Jan 4th, 2024 9:05 pm
Mineralys Therapeutics Announces First Subject Dosed in Launch-HTN, the Second Pivotal Trial of Lorundrostat for the Treatment of Hypertension
- Dec 21st, 2023 9:05 pm
Positive Signs As Multiple Insiders Buy Mineralys Therapeutics Stock
- Nov 27th, 2023 1:12 pm
Mineralys Therapeutics, Inc. (NASDAQ:MLYS) Q3 2023 Earnings Call Transcript
- Nov 12th, 2023 2:22 pm
Mineralys Therapeutics Further Defines Endotype-Specific, Targeted Approach to Treatment of Uncontrolled or Resistant Hypertension with Lorundrostat Data at AHA Scientific Sessions 2023
- Nov 11th, 2023 4:30 pm
Mineralys Therapeutics to Participate in Three Upcoming Conferences
- Nov 9th, 2023 9:05 pm
Mineralys Therapeutics Inc (MLYS) Reports Q3 2023 Financials; R&D Expenses Rise Amid ...
- Nov 7th, 2023 10:12 pm
Mineralys Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate Update
- Nov 7th, 2023 9:05 pm
Mineralys Therapeutics Presents New Post-Hoc Analysis from Target-HTN Phase 2 Trial of Lorundrostat in Late-Breaking Poster Session at ASN Kidney Week 2023 Meeting
- Nov 2nd, 2023 2:00 pm
Mineralys Therapeutics to Announce Third Quarter 2023 Financial Results and Host Conference Call on Tuesday, November 7, 2023
- Oct 31st, 2023 8:05 pm
We're Not Very Worried About Mineralys Therapeutics' (NASDAQ:MLYS) Cash Burn Rate
- Oct 17th, 2023 1:13 pm
Mineralys Therapeutics Announces Upcoming Poster Presentations at Two Scientific Conferences in November 2023
- Oct 13th, 2023 8:10 pm
Scroll